TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34064370
Drug: Unilateral accentuated
Normalized name: Accentrate PNV KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral accentuated eccentric loading (AEL) in the leg press exercise of the dominant leg, performed twice a week for 10 weeks.
Study: 34848566
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours
Study: 32162533
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with BCG
Study: 616026381
Drug: Bimatoprost-timolol fixed
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost-timolol fixed combination (BTFC)
Study: 35970327
Drug: ADT +
Normalized name: Antidepressant+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT + brexpiprazole 2 mg (n = 486)
Study: 35970327
Drug: ADT +
Normalized name: Antidepressant+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT + brexpiprazole 2–3 mg (n = 770)
Study: 34106630
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (vibration and ring massage), once a day, 30 minutes per session, for 5 days, totaling 4 courses of treatment.
Study: 34106630
Drug: Spleen-invigorating bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen-invigorating bolus, orally, twice a day, 1 pill in the morning and 1 pill in the evening, for 5 days, totaling 4 courses of treatment.
Study: 33262252
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - loading dose 1 g over 10 min, then 1 g infusion over 8 hours
Study: 36281683
Drug: Hydromethylthionine mesylate
Normalized name: Hydromethylthionine mesylate
DrugBank: Hydromethylthionine mesylate (DB16899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromethylthionine mesylate 16 mg/day
Study: 36281683
Drug: Hydromethylthionine mesylate
Normalized name: Hydromethylthionine mesylate
DrugBank: Hydromethylthionine mesylate (DB16899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromethylthionine mesylate 8 mg/day
Study: 34275972
Drug: Diabetes codes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes codes and/or prescriptions
Study: 34275972
Drug: Both diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both diabetes codes and prescriptions
Study: 33223374
Drug: Invisalign treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisalign treatment for Class II malocclusion
Study: 33223374
Drug: Invisalign treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisalign treatment for Class I malocclusion
Study: 33027748
Drug: Glucagon-like peptide-1
Normalized name: Glucagon-like peptide-1 (GLP-1) analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Study: 32371731
Drug: 2% chlorhexidine-alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine-alcohol solution
Study: 33648577
Drug: 10% povidone-iodine
Normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% povidone-iodine solution
Study: 34551218
Drug: RBP‐7000 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP‐7000 90 mg
Study: 34551218
Drug: RBP‐7000 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP‐7000 120 mg
Study: 35579143
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dobutamine (infusion rates of 5, 10, 15, and 20 μg/kg/min)
Study: 35965392
Drug: Lotilaner ophthalmic
Normalized name: lotilaner ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner ophthalmic solution, 0.25%
Study: 34000494
Drug: Video intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video intervention administered at the time of the universal newborn hearing screen
Study: 32216109
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg MTX administered subcutaneously once per week for 3 months
Study: 32216109
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg MTX administered subcutaneously
Study: 32216109
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg week−1 MTX (suggested dose)
Study: 34896445
Drug: Nanocort 75
Normalized name: triamcinolone acetonide Injectable Suspension [Cenocort]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocort 75 mg i.v. infusion plus i.m. saline injection
Study: 34896445
Drug: Nanocort 150
Normalized name: triamcinolone acetonide Injectable Suspension [Cenocort]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocort 150 mg i.v. infusion plus i.m. saline injection
Study: 34896445
Drug: Depo‐Medrol® 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo‐Medrol® 120 mg i.m. injection plus i.v. saline infusion
Study: 32807165
Drug: Fortified whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified whey beverage (250 ml daily for 8 weeks)
Study: 36293555
Drug: Xanthohumol (XN)
Normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthohumol (XN) derived from a XN-rich hop extract (75% XN), 0.125 mg
Study: 33113155
Drug: GSK2831781 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 (5 mg/kg)
Study: 33113155
Drug: GSK2831781 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 (0.5, 1.5, and 5 mg/kg)
Study: 34259466
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg orally, followed by a repeat dose after 90 minutes if contractions persisted, continued every 4 hours for 48 hours.
Study: 32770983
Drug: Back in
Normalized name: MENTHOL 0.05 g in 1 g / CAMPHOR (SYNTHETIC) 0.03 g in 1 g TOPICAL CREAM [Healthy Back Institute Rub On Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Back in the Game smartphone application intervention (24-week Internet-delivered programme based on cognitive-behavioural therapy)
Study: 35477496
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of probiotic preparation for 4 weeks
Study: 35477496
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of prebiotic (organic oat bran) supplementation for 4 weeks
Study: 35477496
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of probiotic preparation or 5 g of prebiotic supplementation
Study: 33203440
Drug: Online EMDR
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online EMDR (R-TEP) intervention with a maximum of eight weekly sessions delivered by a trained psychological therapist.
Study: 38319892
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice daily)
Study: 32895647
Drug: Herbal-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal-based oral rinse
Study: 32895647
Drug: 0.12% Chlorhexidine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% Chlorhexidine-based oral rinse
Study: 34998371
Drug: Norepinephrine (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (3.2 μg/min)
Study: 34998371
Drug: Phenylephrine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (40 μg/min)
Study: 35429955
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2 g)
Study: 32900361
Drug: Tramadol (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1-2 mg/kg)
Study: 32900361
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg/kg-i.v.)
Study: 34133087
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure plus sertraline (PE + SERT)
Study: 34133087
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus enhanced medication management (SERT + EMM)
Study: 32006009
Drug: Iron-biofortified beans
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-biofortified beans (Fe-Bean; 86.1 mg Fe/kg)
Study: 32006009
Drug: Conventional beans
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional beans (control: 50.6 mg Fe/kg)
Study: 39087355
Drug: Valsartan treatment
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan treatment
Study: 33545972
Drug: liraglutide once
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide once daily (blinded) combined with glimepiride and metformin
Study: 33545972
Drug: liraglutide placebo
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide placebo once daily (blinded) combined with glimepiride and metformin
Study: 35882823
Drug: Conventional-dose Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose Bacillus coagulans TBC169
Study: 35882823
Drug: High-dose Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Bacillus coagulans TBC169
Study: 36318387
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly (qw)
Study: 36808602
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks (q2w)
Study: 39016623
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg every 2 weeks (q2w)
Study: 35986664
Drug: Dupilumab 100
Normalized name: DUPILUMAB 100MG/0.67ML INJ,SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 100 mg every 4 weeks (q4w)
Study: 34032604
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at sites with the highest intubation rate
Study: 34032604
Drug: Baseline characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline characteristics including seizure precipitant, benzodiazepine dosing, and admission vital signs
Study: 34335455
Drug: Inhibitory repetitive
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitory repetitive Transcranial Magnetic Stimulation (i-rTMS) followed by cognitive treatment for 15 days
Study: 36243386
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 μg inhaled
Study: 36243386
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 400 μg inhaled
Study: 36243386
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 μg twice daily (BID)
Study: 36243386
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 400 μg BID
Study: 36243386
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 μg BID
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 100, 200, 400 μg once daily (QD)
Study: 36243386
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 μg BID
Study: 36243386
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 μg BID
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 800 μg QD
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 644 μg/day
Study: 37880023
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT)
Study: 36739511
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg
Study: 35073398
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of six HLA-DRB1*0401-selective, β-cell peptides administered intradermally at doses of 10, 100, and 500 μg for 24 weeks.
Study: 33987556
Drug: Home-based contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based contraceptive delivery (condoms, pills, injection, implant) during routine 40-day postpartum visit
Study: 35945570
Drug: WhatsApp Messenger
Approvals — FDA: no, EMA: no, PMDA: no
Description: WhatsApp Messenger educational videos (twice a week) + conventional oral health education (single visit)
Study: 35945570
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral health education (single visit)
Study: 33325344
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (Group 3)
Study: 33325344
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics (Group 1)
Study: 33325344
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics (Group 2)
Study: 34239940
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg)
Study: 34239940
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral antihyperglycemic drugs (OADs)
Study: 36775516
Drug: Swedish Massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish Massage Therapy (SMT) for 12 weeks
Study: 36775516
Drug: Swedish Massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish Massage Therapy (SMT) for 6 weeks followed by 6 weeks of light touch (LT)
Study: 36775516
Drug: Swedish Massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish Massage Therapy (SMT)
Study: 33385318
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of dapoxetine hydrochloride
Study: 33385318
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of dapoxetine hydrochloride
Study: 32017646
Drug: Drinkable collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinkable collagen supplement containing special collagen peptides, acerola extract, vitamin C, vitamin E, biotin, and zinc for 12 weeks
Study: 32017646
Drug: Drinkable collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinkable collagen supplement
Study: 33225983
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (5-day treatment)
Study: 33630639
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment with an emphasis on exercise (BT + PA)
Study: 33630639
Drug: Acceptance-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based treatment with an emphasis on exercise (ABT + PA)
Study: 33630639
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment (BT)
Study: 37417824
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonists
Study: 35396952
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise therapy
Study: 35396952
Drug: Non-intensive exercise
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intensive exercise therapy
Study: 36043965
Drug: F4 patch
Normalized name: MLK F4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: F4 patch
Study: 36043965
Drug: F3 patch
Normalized name: MLK F3 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: F3 patch
Study: 35360941
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (117 hips, 36.4% of cases)
Study: 35360941
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (remaining hips)
Study: 32659480
Drug: Voice treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice treatment with physiologic voice therapy plus vocal hygiene program (n=20)
Study: 35277400
Drug: Drug-coating balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coating balloon (DCB) angioplasty
Study: 34491647
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with fire needling therapy and acupoint application therapy
Study: 34491647
Drug: Acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint application therapy
Study: 34491647
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication with pinaverium bromide tablets
Study: 36385642
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion for up to 35 hours
Study: 36385642
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (placebo) for up to 35 hours
Study: 32940404
Drug: Sumac (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumac (3 g/day) with restricted calorie diet (RCD)
Study: 35354633
Drug: Metformin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin added to usual care
Study: 33399374
Drug: 48 mg
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mg dexamethasone
Study: 33608735
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard smoking cessation treatment (behavioral counseling plus self-selected combination NRT)
Study: 32815832
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (80 kV)
Study: 35248270
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) of the temporomandibular joint (TMJ)
Study: 35172859
Drug: Abatacept and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept and/or Methotrexate (treatment withdrawal)
Study: 35749373
Drug: Guideline Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline Daily Amount (GDA)
Study: 33165249
Drug: Medical adhesive
Normalized name: Medical Adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical adhesive treatment after debridement without local anesthesia
Study: 33165249
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment with debridement, local anesthesia, and suture technique without medical adhesive
Study: 32748649
Drug: Daily/near-daily cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily/near-daily cannabis use
Study: 36130180
Drug: Daily positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily positive events reported on 83% of days
Study: 36130180
Drug: Daily negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily negative events reported on 56% of days
Study: 33955250
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus proprioceptive training program
Study: 35429293
Drug: Watermelon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon juice concentrate (WM; 2.2 g·day‐1 L‐citrulline)
Study: 34078638
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) for 12 weeks
Study: 32592568
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (NSAIDs, muscle relaxants, anticonvulsants)
Study: 35942522
Drug: Mesalazine 2400
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine 2400 mg once-daily for 8 weeks
Study: 35942522
Drug: Mucosal patch
Normalized name: benzocaine 15 MG Oromucosal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosal patch technology measures
Study: 36032032
Drug: Pre-incision intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-incision intra-articular injection of 10 mL ropivacaine with epinephrine and 20 mL post-arthrotomy peri-articular injection (PAI)
Study: 36032032
Drug: Standard 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 30 mL post-arthrotomy PAI of ropivacaine with epinephrine
Study: 36059939
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate microspheres 3.75 mg (T)
Study: 36059939
Drug: Enantone® 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enantone® 3.75 mg (R)
Study: 34264737
Drug: Harm-reduction treatment
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harm-reduction treatment for alcohol use disorder (AUD)
Study: 32645160
Drug: Gender-affirming treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-affirming treatment
Study: 32645160
Drug: Other groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other groups (not receiving gender-affirming treatment)
Study: 33232172
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of methylphenidate (MPH)
Study: 37166567
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg ID93 + 5 μg GLA-SE
Study: 37166567
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg ID93 + 5 μg GLA-SE